VA
MYGN icon

Vident Advisory’s Myriad Genetics MYGN Stock Holding History

Vident Advisory’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,848
Closed -$265K – 1499
2024
Q2 		$265K Sell
10,848
-1,603
-13% -$35.2K 0.01% 1171
2024
Q1 		$265K Sell
12,451
-351
-3% -$7.54K 0.01% 1095
2023
Q4 		$245K Buy
12,802
+721
+6% +$12.5K 0.01% 1114
2023
Q3 		$194K Buy
+12,081
New +$230K 0.01% 1126

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Vident Advisory's MYGN Position: Q3 2024 in Review

Vident Advisory sold out of Myriad Genetics (MYGN) in Q3 2024, closing a stake of 10,848 shares — an estimated $265K sold.

Vident Advisory first reported a position in MYGN in Q3 2023 and held it in 4 quarters. The position peaked at $265K in Q1 2024. 246 funds tracked by Wall St. Rank hold MYGN as of Q3 2024.

  • Vident Advisory reported no remaining Myriad Genetics position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 10,848 Myriad Genetics shares in Q3 2024, an estimated $265K.
  • Vident Advisory first reported a position in Myriad Genetics in Q3 2023 and held it in 4 quarters.
  • Vident Advisory's Myriad Genetics position peaked at $265K in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.